secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0000950170-25-012018
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports preliminary Q4 revenue of $13.8M; positive Phase 1/2 data for VYD2311
--------------------------------------------------------------------------------

- Preliminary Q4 PEMGARDA net revenue $13.8M, 48% growth over Q3; total operating costs $32M, 55% reduction.
- Cash and equivalents $69.3M; accounts receivable $10.9M; targets near-term profitability by end of 1H 2025.
- Positive Phase 1/2 data for VYD2311: safety mild/moderate, serum concentrations high at Day 65, half-life not reached.
- VYD2311 shows average 17-fold greater in vitro neutralization potency vs pemivibart across contemporary SARS-CoV-2 variants.
- Potential clinical profile: 70-90% protection from symptomatic COVID-19 with once- or twice-annual dosing, also as treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/0000950170-25-012018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025012018/ivvd-20250203.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-012018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer